Panning of Antibody Phage-Display Libraries: Standard Protocols

2003 ◽  
pp. 133-145 ◽  
Author(s):  
David W. J. Coomber
2003 ◽  
Vol 278 (1-2) ◽  
pp. 271-281 ◽  
Author(s):  
Marja-Leena Laukkanen ◽  
Soili Mäkinen-Kiljunen ◽  
Kirsi Isoherranen ◽  
Tari Haahtela ◽  
Hans Söderlund ◽  
...  

2002 ◽  
Vol 76 (1) ◽  
pp. 251-258 ◽  
Author(s):  
Cristina de Carvalho Nicacio ◽  
R. Anthony Williamson ◽  
Paul W. H. I. Parren ◽  
Åke Lundkvist ◽  
Dennis R. Burton ◽  
...  

ABSTRACT Five human recombinant Fab fragments (Fabs) specific for measles virus (MV) proteins were isolated from three antibody phage display libraries generated from RNAs derived from bone marrow or splenic lymphocytes from three MV-immune individuals. All Fabs reacted in an enzyme-linked immunosorbent assay with MV antigens. In radioimmunoprecipitation assays two of the Fabs, MV12 and MT14, precipitated an ⊘80-kDa protein band corresponding to the hemagglutinin (H) protein from MV-infected Vero cell cultures, while two other Fabs, MT64 and GL29, precipitated an ⊘60-kDa protein corresponding the nucleocapsid (N) protein. In competition studies with MV fusion, H- and N protein-specific monoclonal antibodies (MAbs), the H-specific Fabs predominantly blocked the binding of H-specific MAbs, while the N-specific Fabs blocked MAbs to N. In addition, N-specific Fabs bound to denatured MV N protein in Western blotting. The specificity of the fifth Fab, MV4, could not be determined. By plaque reduction assays, three of the five Fabs, MV4, MV12, and MT14, exhibited neutralizing activity (80% cutoff) against MV (LEC-KI strain) at concentrations ranging between ≈2 and 7 μg ml−1. Neutralization capacity against MV strains Edmonston and Schwarz was also detected, albeit at somewhat higher Fab concentrations. In conclusion, three neutralizing Fabs were isolated, two of them reactive against the H glycoprotein of MV and another reactive against an undefined epitope. This is the first study in which MV-neutralizing human recombinant Fab antibodies have been isolated from phage display libraries.


2015 ◽  
Vol 15 (1) ◽  
pp. 10 ◽  
Author(s):  
Jonas Kügler ◽  
Sonja Wilke ◽  
Doris Meier ◽  
Florian Tomszak ◽  
André Frenzel ◽  
...  

2008 ◽  
Vol 13 (7-8) ◽  
pp. 318-324 ◽  
Author(s):  
David R. Buckler ◽  
Albert Park ◽  
Malini Viswanathan ◽  
Rene M. Hoet ◽  
Robert C. Ladner

Author(s):  
Kristian Daniel Ralph Roth ◽  
Esther Veronika Wenzel ◽  
Maximilian Ruschig ◽  
Stephan Steinke ◽  
Nora Langreder ◽  
...  

Antibodies are essential molecules for diagnosis and treatment of diseases caused by pathogens and their toxins. Antibodies were integrated in our medical repertoire against infectious diseases more than hundred years ago by using animal sera to treat tetanus and diphtheria. In these days, most developed therapeutic antibodies target cancer or autoimmune diseases. The COVID-19 pandemic was a reminder about the importance of antibodies for therapy against infectious diseases. While monoclonal antibodies could be generated by hybridoma technology since the 70ies of the former century, nowadays antibody phage display, among other display technologies, is robustly established to discover new human monoclonal antibodies. Phage display is an in vitro technology which confers the potential for generating antibodies from universal libraries against any conceivable molecule of sufficient size and omits the limitations of the immune systems. If convalescent patients or immunized/infected animals are available, it is possible to construct immune phage display libraries to select in vivo affinity-matured antibodies. A further advantage is the availability of the DNA sequence encoding the phage displayed antibody fragment, which is packaged in the phage particles. Therefore, the selected antibody fragments can be rapidly further engineered in any needed antibody format according to the requirements of the final application. In this review, we present an overview of phage display derived recombinant antibodies against bacterial, viral and eukaryotic pathogens, as well as microbial toxins, intended for diagnostic and therapeutic applications.


Author(s):  
David R. Buckler ◽  
Darren Schofield ◽  
Daniel J. Sexton ◽  
David Lowe ◽  
Tristan J. Vaughan

2012 ◽  
Vol 13 (5) ◽  
pp. 5420-5440 ◽  
Author(s):  
Carmela Dantas-Barbosa ◽  
Marcelo de Macedo Brigido ◽  
Andrea Queiroz Maranhao

Sign in / Sign up

Export Citation Format

Share Document